Russell Investments Group’s Forte Biosciences FBRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.38M Buy
+91,772
New +$2.64M ﹤0.01% 1785
2024
Q4
Sell
-18
Closed -$100 3728
2024
Q3
$100 Hold
18
﹤0.01% 3663
2024
Q2
$243 Hold
18
﹤0.01% 3540
2024
Q1
$317 Hold
18
﹤0.01% 3253
2023
Q4
$372 Hold
18
﹤0.01% 3142
2023
Q3
$299 Hold
18
﹤0.01% 3447
2023
Q2
$471 Hold
18
﹤0.01% 3364
2023
Q1
$457 Hold
18
﹤0.01% 3147
2022
Q4
$453 Hold
18
﹤0.01% 2883
2022
Q3
$0 Hold
18
﹤0.01% 2925
2022
Q2
$0 Hold
18
﹤0.01% 2913
2022
Q1
$0 Hold
18
﹤0.01% 2805
2021
Q4
$0 Hold
18
﹤0.01% 3023
2021
Q3
$1K Hold
18
﹤0.01% 3021
2021
Q2
$15K Hold
18
﹤0.01% 3181
2021
Q1
$15K Buy
+18
New +$14.7K ﹤0.01% 3069
2019
Q1
Sell
-79
Closed -$242K 2937
2018
Q4
$242K Sell
79
-49
-38% -$211K ﹤0.01% 2553
2018
Q3
$747K Sell
128
-88
-41% -$335K ﹤0.01% 2229
2018
Q2
$757K Hold
216
﹤0.01% 2259
2018
Q1
$961K Buy
216
+112
+108% +$519K ﹤0.01% 2218
2017
Q4
$425K Buy
+104
New +$415K ﹤0.01% 2485

Other funds holding FBRX

Russell Investments Group's FBRX Position: Q1 2026 in Review

Russell Investments Group opened a new position in Forte Biosciences (FBRX) in Q1 2026: 91,772 shares worth $2.38M. The stake represents ﹤0.01% of the portfolio and ranks #1785 among its holdings. This is a return to the name: Russell Investments Group previously reported a position in FBRX as recently as Q3 2024.

Russell Investments Group first reported a position in FBRX in Q4 2017 and has held it in 21 quarters since. 68 funds tracked by Wall St. Rank hold FBRX as of Q1 2026.

  • Russell Investments Group held 91,772 shares of Forte Biosciences worth $2.38M as of Q1 2026.
  • Forte Biosciences was a new Russell Investments Group position in Q1 2026.
  • Forte Biosciences made up ﹤0.01% of Russell Investments Group's portfolio in Q1 2026, its #1785 holding.
  • Russell Investments Group first reported a position in Forte Biosciences in Q4 2017 and has held it in 21 quarters since.
  • 68 funds tracked by Wall St. Rank held Forte Biosciences as of Q1 2026.

Based on Russell Investments Group's 13F filing for Q1 2026, filed 8 May 2026.